A M Menzies1, M T Ashworth2, S Swann3, R F Kefford4, K Flaherty5, J Weber6, J R Infante7, K B Kim8, R Gonzalez9, O Hamid10, L Schuchter11, J Cebon12, J A Sosman13, S Little3, P Sun3, G Aktan3, D Ouellet3, F Jin3, G V Long14, A Daud2. 1. Melanoma Institute Australia and The University of Sydney, Sydney, Australia alexander.menzies@sydney.edu.au. 2. University of California San Francisco, San Francisco. 3. Clinical Statistics, GlaxoSmithKline, Collegeville, USA. 4. Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Hospital, University of Sydney, Sydney Westmead Millennium Institute, University of Sydney, Sydney, Australia. 5. Massachusetts General Hospital Center, Boston. 6. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa. 7. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville. 8. California Pacific Medical Center, San Francisco. 9. Department of Medical Oncology, The University of Colorado Cancer Center, Aurora. 10. Department of Oncology, The Angeles Clinic and Research Institute, Santa Monica. 11. Penn Medicine, The University of Pennsylvania, Philadelphia, USA. 12. Oncology Unit, Ludwig Institute for Cancer Research, Heidelberg, Australia. 13. Department of Oncology, Vanderbilt University Medical Centre, Nashville, USA. 14. Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Millennium Institute, University of Sydney, Sydney, Australia.
Abstract
BACKGROUND:Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. PATIENTS AND METHODS: All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naïve patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature ≥38°C (≥100.4(°)F) or related symptoms. RESULTS: Fifty-nine percent of patients developed pyrexia during treatment, 24% of which had pyrexia symptoms without a recorded elevation in body temperature. Pyrexia was grade 2+ in 60% of pyrexia patients. Median time to onset of first pyrexia was 19 days, with a median duration of 9 days. Pyrexia patients had a median of two pyrexia events, but 21% had three or more events. Various pyrexia management approaches were conducted in this study. A trend was observed between dabrafenib and hydroxy-dabrafenib exposure and pyrexia. No baseline clinical characteristics predicted pyrexia, and pyrexia was not statistically significantly associated with treatment outcome. CONCLUSIONS:Pyrexia is a frequent and recurrent toxicity with CombiDT treatment. No baseline features predict pyrexia, and it is not associated with clinical outcome. Dabrafenib and metabolite exposure may contribute to the etiology of pyrexia. The optimal secondary prophylaxis for pyrexia is best studied in a prospective trial.
RCT Entities:
BACKGROUND:Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. PATIENTS AND METHODS: All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naïve patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature ≥38°C (≥100.4(°)F) or related symptoms. RESULTS: Fifty-nine percent of patients developed pyrexia during treatment, 24% of which had pyrexia symptoms without a recorded elevation in body temperature. Pyrexia was grade 2+ in 60% of pyrexiapatients. Median time to onset of first pyrexia was 19 days, with a median duration of 9 days. Pyrexiapatients had a median of two pyrexia events, but 21% had three or more events. Various pyrexia management approaches were conducted in this study. A trend was observed between dabrafenib and hydroxy-dabrafenib exposure and pyrexia. No baseline clinical characteristics predicted pyrexia, and pyrexia was not statistically significantly associated with treatment outcome. CONCLUSIONS:Pyrexia is a frequent and recurrent toxicity with CombiDT treatment. No baseline features predict pyrexia, and it is not associated with clinical outcome. Dabrafenib and metabolite exposure may contribute to the etiology of pyrexia. The optimal secondary prophylaxis for pyrexia is best studied in a prospective trial.
Authors: Jesus Vera; Jonas Paludo; Lisa Kottschade; Jessica Brandt; Yiyi Yan; Matthew Block; Robert McWilliams; Roxana Dronca; Charles Loprinzi; Axel Grothey; Svetomir N Markovic Journal: Support Care Cancer Date: 2019-02-14 Impact factor: 3.603
Authors: Ozlen Saglam; Syeda M H Naqvi; Yonghong Zhang; Tania Mesa; Jamie K Teer; Sean Yoder; Jae Lee; Jane Messina Journal: Melanoma Res Date: 2018-12 Impact factor: 3.599
Authors: David Planchard; Benjamin Besse; Harry J M Groen; Pierre-Jean Souquet; Elisabeth Quoix; Christina S Baik; Fabrice Barlesi; Tae Min Kim; Julien Mazieres; Silvia Novello; James R Rigas; Allison Upalawanna; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson Journal: Lancet Oncol Date: 2016-06-06 Impact factor: 41.316
Authors: Reinhard Dummer; Celeste Lebbé; Victoria Atkinson; Mario Mandalà; Paul D Nathan; Ana Arance; Erika Richtig; Naoya Yamazaki; Caroline Robert; Dirk Schadendorf; Hussein A Tawbi; Paolo A Ascierto; Antoni Ribas; Keith T Flaherty; Neha Pakhle; Catarina D Campbell; Daniel Gusenleitner; Aisha Masood; Jan C Brase; Eduard Gasal; Georgina V Long Journal: Nat Med Date: 2020-10-05 Impact factor: 53.440
Authors: Victoria G Atkinson; Pietro Quaglino; Massimo Aglietta; Michele Del Vecchio; Roberta Depenni; Francesca Consoli; Dimitrios Bafaloukos; Pier Francesco Ferrucci; Skaiste Tulyte; Ivana Krajsová; Paolo A Ascierto; Rossana Gueli; Ana Arance; Helen Gogas; Hiya Banerjee; Teddy Saliba; Egbert de Jong; Bart Neyns Journal: Cancers (Basel) Date: 2021-05-18 Impact factor: 6.639